The impact of SARS-CoV-2 infection on renal function in patients with biopsy-proven kidney diseases
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0296168 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Bogdan Obrișcă und 14 weiteren Autor:innen. Beteiligte Einrichtung: "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania. Hauptthemen laut MEDLINE: Kidney Failure, Chronic, COVID-19. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
We sought to evaluate the long-term effects of COVID-19 on renal function in patients with biopsy-proven kidney diseases.
Methods
A total of 451 patients with biopsy-proven kidney disease and at least 12 months of follow-up subsequent to COVID-19 pandemic onset were included in the study. The primary study endpoint was a composite of a persistent decline of more than 30% in eGFR or ESRD.
Results
23.1% of patients had COVID-19 during a follow-up period of 2.5 y (0.8–2.6), while 17.6% of patients reached the composite endpoint. Those with COVID-19 were more likely to reach the composite endpoint [26.7% vs. 14.8%; OR, 2.1 (95%CI, 1.23–3.58), p = 0.006). There was a significant eGFR change in the first year of follow-up between the two study groups [-2.24 (95%CI,-4.86; 0.37) vs. +2.31 (95%CI, 0.78; 3.85) ml/min, p = 0.004], with an adjusted mean difference of -4.68 ml/min (95%CI,-7.7; -1.59)(p = 0.03). The trend for worse renal outcomes remained consistent in patients with IgAN, MN and FSGS, but not in those with LN. After multivariate adjustment, the independent predictors of the composite endpoint were baseline eGFR (HR, 0.94; 95%CI, 0.92–0.95), COVID-19 (HR, 1.91; 1.16–3.12) and male gender (HR, 1.64; 95%CI, 1.01–2.66). In multivariate linear regression analysis, COVID-19 independently determined a reduction of eGFR at 12 months by 4.62 ml/min/1.73m 2 (β coefficient, -4.62; 95%CI, -7.74 to -1.5, p = 0.004).
Conclusions
There is a significant impact of COVID-19 on long-term renal function in patients with biopsy-proven kidney diseases, leading to a greater decline of eGFR and a worse renal survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
- Department of Nephrology, Fundeni Clinical Institute, Bucharest, Romania.
- Department of Internal Medicine, Fundeni Clinical Institute, Bucharest, Romania.
- Department of Pathology, Fundeni Clinical Institute, Bucharest, Romania.
- 5"Victor Babes" National Institute of Pathology, Bucharest, Romania.
ORCID-Profile: Bogdan Obrișcă
Zitieren
APA
Obrișcă, B., Mocanu, V., Vornicu, A., Jurubiță, R., Sorohan, B., Dimofte, G., Achim, C., Andronesi, A., Micu, G., Bobeică, R., Caceaune, N., Procop, A., Herlea, V., Gherghiceanu, M., & Ismail, G. (2023). The impact of SARS-CoV-2 infection on renal function in patients with biopsy-proven kidney diseases. PLOS ONE. https://doi.org/10.1371/journal.pone.0296168
Vancouver
Obrișcă B, Mocanu V, Vornicu A, Jurubiță R, Sorohan B, Dimofte G, et al. The impact of SARS-CoV-2 infection on renal function in patients with biopsy-proven kidney diseases. PLOS ONE. 2023. doi:10.1371/journal.pone.0296168
BibTeX
@article{Obric2023,
author = {Obrișcă, Bogdan and Mocanu, Valentin and Vornicu, Alexandra and Jurubiță, Roxana and Sorohan, Bogdan and Dimofte, George and Achim, Camelia and Andronesi, Andreea and Micu, Georgia and Bobeică, Raluca and Caceaune, Nicu and Procop, Alexandru and Herlea, Vlad and Gherghiceanu, Mihaela and Ismail, Gener},
title = {The impact of SARS-CoV-2 infection on renal function in patients with biopsy-proven kidney diseases},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0296168}
}
EUVIMED